scholarly journals Endoscopic versus bridging technique of saphenous vein graft harvesting - one-year results

Cor et Vasa ◽  
2012 ◽  
Vol 54 (3-4) ◽  
pp. e93-e96 ◽  
Author(s):  
Vojtěch Kurfirst ◽  
Julia Čanádyová ◽  
Aleš Mokráček
2001 ◽  
Vol 87 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Javed M Ahmed ◽  
George Dangas ◽  
Alexandra J Lansky ◽  
Roxana Mehran ◽  
Mun K Hong ◽  
...  

2017 ◽  
Vol 99 (1) ◽  
pp. 110-117 ◽  
Author(s):  
Yujie Xu ◽  
Zhou Shen ◽  
Gang Liu ◽  
Bing Liu ◽  
Xiaoliang Hua ◽  
...  

2003 ◽  
Vol 91 (10) ◽  
pp. 1250-1254 ◽  
Author(s):  
Thanh T. Nguyen ◽  
William W. O’Neill ◽  
Cindy L. Grines ◽  
Gregg W. Stone ◽  
Bruce R. Brodie ◽  
...  

2005 ◽  
Vol 96 (3) ◽  
pp. 395-398 ◽  
Author(s):  
Keiichi Tsuchida ◽  
Andrew T.L. Ong ◽  
Jiro Aoki ◽  
Carlos A.G. van Mieghem ◽  
Gastón A. Rodriguez-Granillo ◽  
...  

2000 ◽  
Vol 35 (6) ◽  
pp. 1560-1568 ◽  
Author(s):  
Javed M Ahmed ◽  
Mun K Hong ◽  
Roxana Mehran ◽  
Gary S Mintz ◽  
Alexandra J Lansky ◽  
...  

2020 ◽  
Vol 9 (4) ◽  
pp. 1198
Author(s):  
Wojciech Wańha ◽  
Maksymilian Mielczarek ◽  
Natasza Gilis-Malinowska ◽  
Tomasz Roleder ◽  
Marek Milewski ◽  
...  

Background: Evidence concerning the efficacy of the embolic protection devices (EPDs) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI) is sparse. The study was designed to compare major cardiovascular events of all-comer population of SVG PCI with and without EPDs at one year of follow-up. Methods and results: A multi-center registry comparing PCI with and without EPDs in consecutive patients undergoing PCI of SVG. The group comprised 792 patients, among which 266 (33.6%) had myocardial infarction (MI). The primary composite endpoint was major adverse cardiac and cerebrovascular event (MACCE) defined as death, MI, target vessel revascularization (TVR), and stroke assessed at one year. After propensity score analysis, there were no differences in MACCE (21.9% vs. 23.9%; HR 0.91, 95% CI 0.57–1.45, p = 0.681, respectively) nor in secondary endpoints of death, MI, TVR, target lesion revascularization (TLR) and stroke at one year in EPDs PCI group vs. no-EPDs PCI group. Similarly, there were no differences between groups in the study endpoints at 30 days follow-up. Conclusions: There were no clinical benefit for routine use of EPDs during SVG PCI in short and long-term follow-up. Further studies are warranted to explore the effect of individual types of EPDs on clinical outcomes.


Sign in / Sign up

Export Citation Format

Share Document